Pneumonia is a lung infection that annually impacts millions of people around the globe, according to the Centers for Disease ...

Goldman Sachs rates Vaxcyte a buy with $135 price target, highlighting vaccine platform and pneumonia candidate. Read more ...

As we are approaching winter and there is an increase in respiratory diseases, it’s also important to know about pneumococcal ...

The NHS has urged vulnerable people to take two free vaccinations to prevent winter respiratory illnesses. NHS Cambridgeshire ...

The dangerous pneumococcal disease can be fatal to babies and children. Picture: CDC Pediatrician and infectious disease researcher Professor Peter Richmond said declining rates of vaccination ...

Rates of invasive pneumococcal disease are at their highest levels since 2004. While more effective vaccines have been approved for use in Australia, most at-risk people can't get them ...

“New generation vaccines need to be rolled out through the National Immunisation Program without further delay. We simply can’t risk not having the best available pneumococcal protection ...

Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD. Just-reported ...

The City Health Office (CHO) has started providing free vaccines for influenza and pneumonia at local health centers, ...

Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar capturing almost $6 billion of that total in 2020 from its ...

Pneumonia can be caused by a virus, bacteria or fungus. Each of these can cause an immune reaction in the tissues of the ...

Experts believe three factors may be driving the increase in invasive pneumococcal disease: "The challenge is three-fold," added Professor Richmond. "We're seeing a drop in vaccine coverage alongside ...